Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis

Thekla Meyners, Christine Heisterkamp, Jan-Dirk Kueter, Theo Veninga, Lukas J A Stalpers, Steven E Schild, Dirk Rades, Thekla Meyners, Christine Heisterkamp, Jan-Dirk Kueter, Theo Veninga, Lukas J A Stalpers, Steven E Schild, Dirk Rades

Abstract

Background: This study investigated potential prognostic factors in patients treated with whole-brain irradiation (WBI) alone for brain metastases from relatively radioresistant tumors such as malignant melanoma, renal cell carcinoma, and colorectal cancer. Additionally, a potential benefit from escalating the radiation dose was investigated.

Methods: Data from 220 patients were retrospectively analyzed for overall survival and local control. Nine potential prognostic factors were evaluated: tumor type, WBI schedule, age, gender, Karnofsky performance score, number of brain metastases, extracerebral metastases, interval from diagnosis of cancer to WBI, and recursive partitioning analysis (RPA) class.

Results: Survival rates at 6 and 12 months were 32% and 19%, respectively. In the multivariate analysis, WBI doses >30 Gy (p = 0.038), KPS ≥70 (p < 0.001), only 1-3 brain metastases (p = 0.007), no extracerebral metastases (p < 0.001), and RPA class 1 (p < 0.001) were associated with improved survival. Local control rates at 6 and 12 months were 37% and 15%, respectively. In the multivariate analyses, KPS ≥70 (p < 0.001), only 1-3 brain metastases (p < 0.001), and RPA class 1 (p < 0.001) were associated with improved local control. In RPA class 3 patients, survival rates at 6 months were 10% (35 of 39 patients) after 10 × 3 Gy and 9% (2 of 23 patients) after greater doses, respectively (p = 0.98).

Conclusions: Improved outcomes were associated with WBI doses >30 Gy, better performance status, fewer brain metastases, lack of extracerebral metastases, and lower RPA class. Patients receiving WBI alone appear to benefit from WBI doses >30 Gy. However, such a benefit is limited to RPA class 1 or 2 patients.

References

    1. Morris SL, Low SH, A'Hern RP, Eisen TG, Gore ME, Nutting CM, Harrington KI. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer. 2004;91:829–833.
    1. Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997;37:753–759.
    1. Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998;83:2548–2553. doi: 10.1002/(SICI)1097-0142(19981215)83:12<2548::AID-CNCR21>;2-4.
    1. Maor MH, Frias AE, Oswald MJ. Palliative radiotherapy for brain metastases in renal carcinoma. Cancer. 1988;62:1912–1917. doi: 10.1002/1097-0142(19881101)62:9<1912::AID-CNCR2820620908>;2-T.
    1. Kruser TJ, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Pelley R, Suh JH. Multidisciplinary management of colorectal brain metastases. A retrospective study. Cancer. 2008;113:158–165. doi: 10.1002/cncr.23531.
    1. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5:108–113. doi: 10.3816/CCC.2005.n.022.
    1. Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20. doi: 10.3171/jns.1998.88.1.0011.
    1. Cannady SB, Cavanaugh KA, Lee SY, Bukowski RM, Olencki TE, Stevens GHJ, Barnett GH, Suh JH. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys. 2004;58:253–258. doi: 10.1016/S0360-3016(03)00818-6.
    1. Hammoud MA, McCutcheon IE, Elsouki R, Schoppa D, Patt YZ. Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. Ann Surg Oncol. 1996;3:453–463. doi: 10.1007/BF02305763.
    1. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751.
    1. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi: 10.2307/2281868.
    1. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13–47.
    1. Farnell GF, Buckner JC, Cascino TL, O'Connell MJ, Schomberg PJ, Suman V. Brain metastases from colorectal carcinoma. The long term survivors. Cancer. 1996;78:711–716. doi: 10.1002/(SICI)1097-0142(19960815)78:4<711::AID-CNCR3>;2-H.
    1. Ikushima H, Tokuuye K, Sumi M, Kagami Y, Murayama S, Ikeda H, Tanaka M, Oyama H, Shibui S, Nomura K. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;48:1389–1393.
    1. Dziggel L, Veninga T, Haatanen T, Lohynska R, Schild SE, Rades D. Scoring systems predictive of survival and local control of patients irradiated for brain metastases [abstract] J Clin Oncol. 2009;27:15s. doi: 10.1200/JCO.2008.21.7695. (abstr 2075)
    1. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC, Kalkanis SN. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:17–32. doi: 10.1007/s11060-009-0060-9.
    1. Joiner MC, Van der Kogel AJ. In: Basic clinical radiobiology. Steel GG, editor. New York: Oxford University Press; 1997. The linear-quadratic approach to fractionation and calculation of isoeffect relationships; pp. 106–112.
    1. Isokangas OP, Muhonen T, Kajanti M, Pyrhonen S. Radiation therapy of intracraial malignant melanoma. Radiother Oncol. 1996;38:139–144. doi: 10.1016/0167-8140(95)01691-0.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner